Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | QDPR | P09417 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554085 | 0.81 | SPR (0.32) | MEN1KMT2A | |
| SCHEMBL1271474 | 0.81 | SMN1; SMN2 (0.45) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL20609927 | 0.79 | EPHX2 (0.42) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL1271472 | 0.79 | KDM4E (0.43) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL18711326 | 0.76 | PIK3CD (0.40) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL18711315 | 0.76 | EPHX2 (0.43) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL20600286 | 0.76 | GAA (0.56) | TDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11850495 | 0.75 | CYP1A2 (0.50) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL56603 | 0.74 | HPGD (0.53) | EPHX1KDM4ESMN1; SMN2 | |
| SCHEMBL4183478 | 0.73 | SPR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645533-B1 | TDO2 AND IDO1 INHIBITORS | GENENTECH INC (US) | 2025-03-26 | — | — | EP | disclosed |
| US-11603373-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3645533-A1 | TDO2 AND IDO1 INHIBITORS | Genentech, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200123163-A1 | TDO2 and IDO1 Inhibitors | GENENTECH, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-2019005559-A1 | TDO2 AND IDO1 INHIBITORS | GENENTECH, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603373-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | EPHX2 1699/4885EPHX1 1619/4885CYP1A2 95/4885 |
| US-20200123163-A1 | TDO2 and IDO1 Inhibitors | IDO1, TDO2, IDO2 | EPHX2 1699/4885EPHX1 1619/4885CYP1A2 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.